RR International Pharma Journal (RRIPJ)
Volume 3, Issue 2, July-December, 2025, ISSN 3079-4684

HIV/TB Co-infection: Restoring Immunity in Early HIV Infection through Tuberculosis Treatment

Dr. Ashok Kumar

Medical Laboratory Technician, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana

ABSTRACT

Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) represent two of the most devastating infectious diseases worldwide, particularly when they occur as co-infections. HIV weakens host immunity, dramatically increasing susceptibility to Mycobacterium tuberculosis, while TB accelerates HIV disease progression by enhancing immune activation and viral replication. Early HIV infection presents a critical window of opportunity for immune restoration, especially when TB is promptly diagnosed and treated.

This review explores the immunopathogenesis of HIV/TB co-infection, mechanisms of immune suppression, and emerging evidence on how early TB treatment contributes to immune reconstitution in HIV-infected individuals. Emphasis is placed on cellular and cytokine-level immune recovery, timing of antiretroviral therapy (ART), TB-associated immune activation, and strategies to optimize immune restoration. The article integrates immunological, clinical, and therapeutic perspectives, highlighting future research directions for improving outcomes in HIV/TB co-infected patients.

Keywords: HIV, Tuberculosis, Co-infection, Immune Restoration, ART, Immune Reconstitution, Early HIV

INTRODUCTION

HIV and TB together form a lethal syndemic, particularly in low- and middle-income countries. TB remains the leading cause of death among people living with HIV (PLHIV). HIV-induced immunosuppression increases the risk of TB reactivation, while active TB exacerbates HIV replication and immune decline.

Early HIV infection is characterized by intense immune activation, rapid depletion of $CD4^+$ T cells—especially in gut-associated lymphoid tissue—and establishment of viral reservoirs. TB co-infection during this stage further disrupts immune homeostasis. However, emerging evidence suggests that **early diagnosis and treatment of TB**—along with timely initiation of ART—can partially restore immune function and reduce long-term immunological damage.

This review synthesizes existing literature to examine how TB treatment influences immune restoration in early HIV infection and outlines immunological mechanisms, clinical outcomes, and therapeutic strategies.

2. Global Burden of HIV/TB Co-infection

HIV/TB co-infection continues to be a major global public health challenge.

Table 1: Global Overview of HIV/TB Co-infection

Parameter	Estimate
People living with HIV worldwide	~39 million
TB cases annually	~10 million
TB deaths among PLHIV	~300,000/year
Increased TB risk in HIV	18–25×
High-burden regions	Sub-Saharan Africa, South Asia

The overlap of these epidemics is driven by poverty, malnutrition, overcrowding, limited healthcare access, and delayed diagnosis.

3. Immunopathogenesis of HIV Infection

HIV primarily targets $CD4^+$ T lymphocytes, macrophages, and dendritic cells. Immune damage begins early after infection.

Key immunological changes in early HIV:

- Rapid $CD4^+$ T-cell depletion
- Chronic immune activation
- Cytokine imbalance (↑ TNF-α, IL-6, IFN-γ)
- Loss of mucosal immunity
- Establishment of latent viral reservoirs





Persistent immune activation, rather than viral load alone, is a major driver of disease progression.

4. Immunology of Tuberculosis

TB is a complex intracellular infection requiring a coordinated immune response.

Protective immune mechanisms in TB:

- Th1-mediated immunity
- IFN-γ production
- Macrophage activation
- Granuloma formation

Immune evasion by *Mycobacterium tuberculosis*:

- Inhibition of phagosome-lysosome fusion
- Suppression of antigen presentation
- Modulation of host cytokine responses

In immunocompetent hosts, TB infection may remain latent. In HIV-infected individuals, immune control fails, leading to active disease.

5. Immunopathogenesis of HIV/TB Co-infection

HIV and TB act synergistically to worsen immune dysfunction.

Mechanisms of synergy:

- TB-induced immune activation enhances HIV replication

- HIV reduces TB-specific $CD4^+$ T-cell responses
- Increased pro-inflammatory cytokines
- Accelerated $CD4^+$ T-cell loss

Table 2: Immunological Interactions in HIV/TB Co-infection

Immune Component	Effect
$CD4^+$ T cells	Profound depletion
Macrophages	HIV replication reservoirs
Cytokines	TNF-α, IL-6 ↑
Granulomas	Disrupted structure
Viral load	Increased during TB

This bidirectional interaction creates a vicious cycle of immune deterioration.



6. Early HIV Infection: A Window for Immune Restoration

Early HIV infection represents a critical phase where immune damage is partially reversible.

Characteristics:

- High viral replication
- Intense immune activation
- Partial preservation of immune architecture

Intervening during this stage—especially by treating co-existing TB—can limit irreversible immune injury.

7. Impact of TB Treatment on Immune Restoration

TB treatment reduces mycobacterial load, inflammation, and immune activation.

Immunological benefits of TB therapy:

- Reduced antigenic stimulation
- Decreased pro-inflammatory cytokines
- Improved macrophage function
- Enhanced TB-specific T-cell responses

Studies show that successful TB treatment leads to:

- Increased $CD4^+$ T-cell counts
- Reduced immune exhaustion markers
- Improved immune responsiveness to ART

8. Timing of Antiretroviral Therapy in HIV/TB Co-infection

Early ART initiation is crucial but must be balanced against complications such as Immune Reconstitution Inflammatory Syndrome (IRIS).

Current evidence:

- ART within 2–8 weeks of TB treatment improves survival
- Early ART promotes faster immune recovery
- Delayed ART increases mortality

Table 3: Benefits and Risks of Early ART in TB Co-infection

Aspect	Outcome
CD4 recovery	Improved
Viral suppression	Faster
Mortality	Reduced
IRIS risk	Increased but manageable

9. Immune Reconstitution Inflammatory Syndrome (IRIS)

IRIS is a paradoxical inflammatory reaction following immune recovery.

Risk factors:

- Low baseline CD4 count
- High TB antigen burden
- Rapid immune restoration

Immunological basis:

- Sudden restoration of pathogen-specific immune responses
- Excessive cytokine release

Despite IRIS risk, early ART remains beneficial overall.

10. Cytokine and Biomarker Changes During Immune Restoration

TB treatment and ART lead to measurable changes in immune markers.

Table 4: Immunological Biomarkers in Immune Restoration

Marker	Change After Treatment
$CD4^+$ T cells	↑
Viral load	↓
TNF-α	↓
IL-6	↓
IFN-γ	Normalized

Monitoring these biomarkers helps assess immune recovery.

11. Role of Innate Immunity in Immune Restoration

Innate immune cells play a foundational role.

Key players:

- Macrophages
- Natural killer (NK) cells
- Dendritic cells

TB treatment restores macrophage antimicrobial function, while ART improves NK cell activity and antigen presentation.

12. Gut Immunity and Microbial Translocation

Early HIV damages gut-associated lymphoid tissue, leading to microbial translocation and chronic immune activation.

TB treatment indirectly reduces systemic inflammation, facilitating gut immune repair when combined with ART.

13. Special Populations and Clinical Considerations

Children:

- Faster immune recovery
- Lower TB-related mortality

Pregnant women:

- Higher TB risk
- Immune restoration critical for maternal-fetal health

Drug-resistant TB:

- Delayed immune recovery
- Higher mortality

14. Therapeutic Strategies to Enhance Immune Restoration

Emerging strategies include:

- Optimized ART timing
- Host-directed therapies
- Anti-inflammatory agents
- Nutritional supplementation
- Therapeutic vaccines

These approaches aim to restore immune balance without excessive inflammation.

15. Future Research Directions

Key research gaps:

- Long-term immune recovery outcomes
- Biomarkers predicting immune restoration
- Strategies to reduce IRIS
- Immune-modulatory therapies

Precision medicine approaches may individualize HIV/TB management.

CONCLUSION

HIV/TB co-infection represents a complex immunological challenge. Early HIV infection offers a unique opportunity for immune restoration, particularly when TB is promptly treated. TB therapy reduces immune activation, improves cellular immune responses, and enhances the effectiveness of ART. Integrated, early, and immune-focused treatment strategies are essential to improving survival and quality of life in co-infected patients. Continued research into immune restoration mechanisms will guide the development of more effective therapeutic interventions.

REFERENCES

[1]. Lawn, S. D., & Churchyard, G. J. (2009). Epidemiology of HIV-associated tuberculosis. Current Opinion in HIV and AIDS, 4(4), 325–333.

[2]. Gupta, A., Wood, R., Kaplan, R., Bekker, L. G., & Lawn, S. D. (2013). Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa. AIDS, 27(1), 89–97.

[3]. Meintjes, G., Lawn, S. D., Scano, F., et al. (2008). Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. The Lancet Infectious Diseases, 8(8), 516–523.

[4]. World Health Organization. (2023). Global tuberculosis report 2023. WHO Press.

[5]. UNAIDS. (2023). Global HIV & AIDS statistics — Fact sheet. UNAIDS.

[6]. Kwan, C. K., & Ernst, J. D. (2011). HIV and tuberculosis: A deadly human syndemic. Clinical Microbiology Reviews, 24(2), 351–376.

[7]. Lawn, S. D., Harries, A. D., Williams, B. G., et al. (2011). Antiretroviral therapy and the control of HIV-associated tuberculosis. The Lancet Infectious Diseases, 11(5), 378–388.

[8]. Abdool Karim, S. S., Naidoo, K., Grobler, A., et al. (2010). Timing of initiation of antiretroviral drugs during tuberculosis therapy. New England Journal of Medicine, 362(8), 697–706.

[9]. Havlir, D. V., Kendall, M. A., Ive, P., et al. (2011). Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. New England Journal of Medicine, 365(16), 1482–1491.

[10]. Suthar, A. B., Lawn, S. D., del Amo, J., et al. (2012). Antiretroviral therapy for prevention of tuberculosis in adults with HIV: A systematic review and meta-analysis. PLoS Medicine, 9(7), e1001270.

[11]. Esmail, H., Riou, C., Bruyn, E. D., et al. (2018). The immune response to Mycobacterium tuberculosis in HIV-1–coinfected persons. Annual Review of Immunology, 36, 603–638.

[12]. Brenchley, J. M., Price, D. A., & Douek, D. C. (2006). HIV disease: Immune activation and immune damage. Current Opinion in HIV and AIDS, 1(1), 22–30.

[13]. Deeks, S. G., Kitchen, C. M. R., Liu, L., et al. (2004). Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood, 104(4), 942–947.

[14]. Day, C. L., Kaufmann, D. E., Kiepiela, P., et al. (2006). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 443(7109), 350–354.

[15]. Wilkinson, R. J., Lai, R., Meintjes, G., & Pepper, D. J. (2015). Immune reconstitution inflammatory syndrome in HIV-infected patients with tuberculosis and cryptococcal meningitis. Current Opinion in Infectious Diseases, 28(5), 404–410.

[16]. Barber, D. L., Mayer-Barber, K. D., Feng, C. G., Sharpe, A. H., & Sher, A. (2011). CD4 T cells promote rather than control tuberculosis in the absence of PD-1–mediated inhibition. Journal of Immunology, 186(3), 1598–1607.

[17]. Murray, J. F. (2015). Tuberculosis and HIV infection during the antiretroviral era. Annual Review of Medicine, 66, 457–468. https://doi.org/10.1146/annurev-med-050913-022626

[18]. Cain, K. P., Anekthananon, T., Burapat, C., et al. (2009). Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerging Infectious Diseases, 15(2), 258–264.

[19]. French, M. A., Price, P., & Stone, S. F. (2004). Immune restoration disease after antiretroviral therapy. AIDS, 18(12), 1615–1627.

[20]. Gupta, A., Nadkarni, G., Yang, W. T., et al. (2011). Early mortality in adults initiating antiretroviral therapy (ART) for HIV/TB co-infection. AIDS, 25(10), 1275–1282.

[21]. Ravimohan, S., Kornfeld, H., Weissman, D., & Bisson, G. P. (2018). Tuberculosis and lung damage: From epidemiology to pathophysiology. European Respiratory Review, 27(147), 170077.

[22]. Lalvani, A., & Pareek, M. (2010). Interferon gamma release assays: Principles and practice. Enfermedades Infecciosas y Microbiología Clínica, 28(4), 245–252.

[23]. Doitsh, G., & Greene, W. C. (2016). Dissecting how CD4 T cells are lost during HIV infection. Cell Host & Microbe, 19(3), 280–291.

[24]. Geldmacher, C., Schuetz, A., Ngwenyama, N., et al. (2010). Early depletion of Mycobacterium tuberculosis–specific T helper 1 cell responses after HIV-1 infection. Journal of Infectious Diseases, 201(10), 1590–1598.

[25]. Autran, B., Carcelain, G., Li, T. S., et al. (1997). Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science, 277(5322), 112–116.

[26]. Mangino, J. E., & Moore, R. D. (2000). Immune reconstitution inflammatory syndrome. Current Infectious Disease Reports, 2(5), 411–418.

[27]. Sodora, D. L., & Silvestri, G. (2008). Immune activation and AIDS pathogenesis. AIDS, 22(4), 439–446.

[28]. Wilkinson, K. A., Oni, T., Gideon, H. P., et al. (2016). Activation profile of Mycobacterium tuberculosis–specific CD4 T cells reflects disease activity irrespective of HIV status. American Journal of Respiratory and Critical Care Medicine, 193(11), 1307–1310.